Virbac SA, a pharmaceutical company based in France, specializes in manufacturing drugs for animal health. With a Risk Rating Score of 21.1, the company is categorized as having a medium risk assessment. Virbac SA generates most of its revenue in Europe, with additional income coming from Asia and Latin America. The company's strong focus on ESG principles sets it apart in the industry.